| abstract |
The present disclosure relates to the finding that microRNA- 155 plays a role in the development and activity of CD4+ T cells. CD4+ T cell development and function, particularly T H 17 and T H 1 T cell development, can be modulated by delivery of microRNA- 155 (miR-155) or antisense miR-155 to target CD4+ cells or precursor cells. In some embodiments, antisense miR-155 is used to reduce tissue specific autoimmune inflalmmation and to treat autoimmune disease. In addition, miR155 and antisense miR-155 can be used to modulate expression of cytokines from dendritic cells. |